Genetic Counselling and Presymptomatic Genetic Testing
Goals and Ethics for Clinical Practice, Caring and Education

page updated september 9, 2005.

Participants
Christian Munthe (project leader), Ph.D. & Professor, Dept. of Philosophy, Gothenburg University
Karin Ahlberg (f.d. Magnusson), Qualified Nurse, Ph.D., Dept. of Oncology & Dept. of Caring Science, Sahlgrenska University Hospital
Annika Baan, Qualified Nurse, Dept. of Oncology, Sahlgrenska University Hospital
Karin Bengtsson, B.Sc., M.A. of Bioethics, Ph.D.-student, Dept. of Clinical Genetics, Sahlgrenska University Hospital/East and Department of Theology, Uppsala University.
Zakaria Einbeigi, MD, Dept. of Oncology, Sahlgrenska University Hospital
Ulrika Hösterey-Ugander, Qualified Psychologist, Dept. of Clinical Genetics, Sahlgrenska University Hospital/East
Niklas Juth, Ph.D., Deputy Lecturer, Dept. of Philosophy, Gothenburg University
Per Karlsson, MD, Dept. of Oncology, Sahlgrenska University Hospital
Göran Lantz, Ph.D. & Professor, Department of Theology, Uppsala University.
Jan Wahlström, MD & Professor, Dept. of Clinical Genetics, Sahlgrenska University Hospital/East
Arne Wallgren, MD & Professor, Dept. of Oncology, Sahlgrenska University Hospital

Time
2000-2006

Administrating institution
Dept. of Philosophy, Gothenburg University

Funding
The Swedish Ethics in Health Care Program, the Jubillee Foundation at the Sahlgrenska University Hospital, Participating departments

Keywords
autonomy, bioethics, cancer, caring science, education, ethics, genetic counselling, genetic testing, Huntington's disease, medical ethics, psychology


GO TO
Project description
Summary
Background
References
Questions and Methods
Publications and presentations and activities

<>PROJECT DESCRIPTION


SUMMARY
Ethical, educational, organisation and caring aspects of presymptomatic genetic testing are studied at clinics where such testing is offered, as well as an education for genetic counsellors. The main question is how clinical practice and education in this area have been and should be organised with respect to caretaking, handling of information and introduction of new tests. The project investigates how patients, relatives and personell perceive the process, in particular the ability of patients to understand information and implement it in decision making. The attitudes of relatives to patients are studied as to whether or not they want information relevant for their own genetic status resulting from the testing of other persons. Assuming that well-being and autonomy are the chief ethical values at stake in this practice, two basic ethical issues are investigated: First, what determines the extent to which presymptomatic genetic information can serve these values? Secondly, how should conflicts of interest between patients and other parties (e.g., relatives) regarding access to genetic information be viewed in the face of these values?

BACKGROUND
Genetic counselling (GC) once evolved as the use of health-related information about families uncommonly burdened by some disease in order to estimate and communicate the statistical risk of contracting this disease. In later years, the applicability of GC has become more wide and precise due to the possibility of DNA-level genetic testing and the knowledge from the Human Genome Project, but family-examinations is still the basic tool of any genetic counsellor. Originally entangled with eugenic concerns for the "quality" of the population (Adams 1990, Broberg & Roll-Hansen 1995, Youngson & Schott 1996), the ideal of contemporary GC is instead often formulated as non-directiveness: The task is to provide neutral information in order to protect and promote the personal autonomy of individuals - i.e., to help them direct their own lives according to their own liking. However, this ideal has proved difficult to implement due to a number of factors, such as the anxiety and guilt-feelings linked to hereditary disease in the minds of many people, the peculiarity of genetic information to be about whole families, the difficulties involved in explaining complex genetic risks, and the simple fact that different people value genetic information and the actions which may be undertaken on the basis of it quite differently. Partly due to this, the goal of non-directiveness has become increasingly controversial. (Caplan 1993, Clarke 1994, Harper & Clarke 1997, Murray & Botkin 1995, Wertz & Fletcher 1989, and Wertz, Fletcher, Berg & Boulyjenkov 1995). Moreover, since the autonomous choices of individuals are not necessarily beneficial for their health and well-being, the ideal of GC and the traditional goals of health care may conflict sharply.
 For long, GC has been a rather small activity, concerning only rare conditions in especially burdened "risk-families". However, due to the conclusion of the human genome project, as well as the fast development of testing technologies and associated therapies, genetic testing and GC will soon be actualised for a much larger population, as well as a much wider spectrum of conditions.
 Genetic testing can be used for different purposes, such as prenatal diagnosis (surrounded by its own peculiar ethical complications (Handyside 1996, Munthe 1996, Munthe 1999, Verlinsky & Kuliev 1998)), or clinical diagnosis of people suffering from some symptoms. A third purpose is the investigation of the possibility that a person with no symptoms will in the future contract some disease - so-called presymptomatic genetic testing (PGT). PGT is actualised in connection to so-called late onset diseases (LOD), i.e. symptoms start to appear a period into the life of the person in question. Testing for LOD is often actualised by diagnosis or PGT of a kin. However, in the future, PGT may also be demanded as a spin-off effect of genetic testing necessary for new pharmaceutical therapies, increased public awareness of genetics and pressure from societal and commercial parties (Draper 1991, Duster 1990, Weir, Lawrence & Fales 1994, Hubbard & Wald 1993, Munthe 1998). The heredity of LOD vary significantly, from monogenic heredity, where the disease is a direct result of a single mutation, to various forms of complex heredity, where there is an interplay of several genes and environmental factors. PGT for complex diseases can only inform about the risk of a certain individual to become sick ? a risk which may vary a lot depending on the number of genes involved, different populations, families, life-styles, environment, work etc. Recently identified genes for various forms of cancer are all examples of complex diseases and several very common diseases (e.g., diabetes and cardiac problems) has a very complex heredity.
 All this means that many more health care professionals than before, as well as whole new categories of staff, will have to deal with the known practical and ethical problems of PGT and GC. At the same time, the growing knowledge about the complex diseases is making these problems even more difficult to handle. (Dahlqvist & Wahlström 1997). For a long time, this will be further complicated by the dynamic nature of genetic knowledge, where new investigations will lead to repeated adjustments of assessed genetic risks. At the same time, the number of patients in PGT will most probably increase significantly. This will in turn further complicate the practice of GC, since different individuals react very different to the idea of PGT, the information about genetic risks and the varying possibilities of treatment. This also complicates the assessment as to whether or not a certain test is "good enough" in order to be offered and whether or not the obtaining of informed consent is practically possible. (Faden & Beauchamp 1986, Jonsson 1994, Munthe 1999). Moreover, the development that PGT and GC is brought into new areas of health care where the standard is the traditional goals of medicine actualises the possibility of conflict between these goals and the ideal of GC.
 All these scenarios actualise basic questions of how the caretaking of patients in PGT and related GC should be handled, to what extent the GC of today live up to these requirements and on what conditions it may do so in the future. One aspect of this is on what grounds one should decide whether or not a new possibility of PGT should be offered at all. What should be seen as the benefits of PGT? How should these be balanced against risks? Can health care really withhold tests which are in demand for the reason that they are seen as "not good enough" in light of the ideal to promote (not only respect) autonomy? Other problems instead concern the practice before and after testing. In Sweden, GC has traditionally been handled by specialists in clinical genetics, but as we have just seen, this situation is already changing and will change even more. One action for dealing with this to increase the general knowledge among health care staff (Wertz, Fletcher, Berg et.al. 1995), but this may not be practically possible. One way of meeting this challenge is to develop a system with so-called genetic counsellors, i.e. people (often specialised nurses or almoners) who are not specialists in genetics but who have a special competence to handle the problems actualised in GC and to care for the special needs arising in this context. Such people will, of course, need deepened insights into the ethical problems actualised by PGT. This modell has been used in the USA and the United Kingdom, but in Sweden it has just been initiated through a newly started education for genetic counsellors in Gothenburg which is led by one of the participants in this project (U H-U). Still, even in an international perspective, it is highly unclear how the professionalisation of such a new speciality connects to the complexity of the ethics and practical conditions of future GC (Kenen 1997).
 A third and very peculiar complex of problems concern how the information obtained by PGT should be handled in relation to various third parties, in particular relatives. The tradition in Sweden has been to inform the patient and then let her decide whether or not to inform relatives (Arbetsgruppen för cancergenetiska mottagningar i Sverige 1998 & 1999). In other parts of the world, however, very different approaches are in use (Wertz & Fletcher 1989), something which is of interest in the Swedish context, since an increase of the number patients in PGT will most certainly also involve an increase of patients from different cultural backgrounds. The Swedish model may seem to respect the integrity of the patient, but at the same time it means that the patient obtains information about the relatives which they may not want the patient to have. Another reason for this model is the uncertainty as to whether or not relatives really want to be informed, but this problem seems to remain with the present practice since the patient need not know more about this. Moreover, the patient is probably less competent to provide GC to relatives than health care staff. The praxis also seems to be modelled on a rather simplified picture of how family-links interplay with psychological relations between people, which means that different relatives may be treated rather differently by the patient - something which may seem problematic from the point of view of justice (Ruyter & Storvik 1996). However, in the light of other parties which may be interested in the information from PGT (employers, insurance etc.), for health care to be prepared to disseminate information about patients against their wishes may seem rather horrifying.
 Besides various descriptive facts, in order to analyse these problems, a theory of the ethics of autonomy which can handle interpersonal conflicts of autonomy arising out of the ideal of GC not only to respect (as in traditional medical ethics) but also to actively promote people´s autonomy is needed. However, standard autonomy-centred ethical theories (Kantian, Lockean, Millean and most contract- theories) in medical as well as general normative ethics as a rule prescribe only a duty to respect autonomy and thus do not allow for such conflicts to arise. For this reason, they are also incapable of providing guidance regarding how gains in autonomy should be balanced against losses of other values. It is therefore highly unclear on what grounds such conflicts as well as interpersonal conflicts of autonomy between patients and should be resolved.

REFERENCES
Adams M D (ed.) 1990, The Wellborn Science. Eugenics in Germany, France, Brazil and Russia. New York & Oxford 1990: Oxford University Press.
Arbetsgruppen för cancergenetiska mottagningar i Sverige 1999, Utredning, uppföljning och omhändertagande av personer med misstänkt ärftligt ökad risk för tumörsjukdom: Allmän översikt.
 ? 1998, Utredning, uppföljning och omhändertagande av personer med misstänkt ärftligt ökad risk för tumörsjukdom: Etiska överväganden.
Bartels D M, LeRoy B S, Caplan A L (eds.) 1993, Prescribing Our Future. Ethical Challenges in Genetic Councelling. New York 1993: Aldine De Gruyter.
Clarke, A 1994 (ed.), Genetic Councelling. Practice and Principles, London & New York 1994: Routledge.
Dahlqvist G, Wahlström J 1997, "Etiska problem när genteknik blir klinisk rutin". Läkartidningen 1997, 94:3044-3046, 3048-3050.
Draper E 1991, Risky Business. Genetic Testing and Exclusionary Practices in the Hazardous Workplace. Cambridge 1991: Cambridge University Press.
Duster T 1990, Backdoor to Eugenics. London & New York: Rotledge.
Faden R R, Beauchamp T L 1986, A History and Theory of Informed Consent. Oxford 1986: Oxford University Press.
Harper P S, Clarke A J 1997, Genetics, Society and Clinical Practice. Oxford 1997: BIOS Scientific Publishers.
Hubbard R, Wald E 1993, Exploding the Gene Myth: How Genetic Information is Produced and Manipulated by Scientists, Physicians, Employers, Insurance Companies, Educators, and Law Enforcers. Boston 1993: Beacon Press.
Kenen, R H 1997, "Opportunities and impediments for a consolidating and expanding profession: genetic counselling in the United States", Social Science and Medicine 45: 1377-1386.
Munthe 1996, The Moral Roots of Prenatal Diagnosis. Ethical Aspects of the Early Introduction and Presentation of Prenatal Diagnosis in Sweden. Studies in Research Ethics no. 7. Göteborg 1996: Centre for Research Ethics.
- 1998, "Kunskap för vem? Gentestningens etik och politik", i Nilsson A (ed.) 1998, Gentest ? för vem?. Källa no. 50, Stockholm 1998: Forskningsrådsnämnden.
- 1999, Pure Selection. The Ethics of Preimplantation Genetic Diagnosis and Choosing Children without Abortion, Göteborg 1999: Acta Universitatis Gothoburgensis.
Ruyter K, Storvik H (eds.) 1996, Oppsøkende genetisk veiledning. Oslo 1996: De nasjonale forskningsetiske komitéer.
Weir R F, Lawrence S C & Fales E (eds.) 1994, Genes and Human Self-knowledge. Iowa City 1994: Iowa University Press.
Wertz D C, Fletcher J C (eds.) 1989, Ethics and Human Genetics. A Cross-Cultural Perspective. Berlin 1989: Springer-Verlag.
Wertz D C, Fletcher J C, Berg K, Boulyjenkov V 1995, Guidelines on Ethical Issues in Medical Genetics and the Provision of Genetic Services. Genéve 1995: World Health Organisation.
Youngson R & Schott I 1996, Medical Blunders. London 1996: Robinson Publ. Ltd.
 

QUESTIONS, METHODS & ETHICS
The project will run for 4 years, and its main questions will be: 1. How should caretaking of patients in connection to PGT be handled and organised? 2. What determines whether or not a new application of PGT should be offered? 3. How should information obtained by PGT be handled in relation to third parties (in particular, relatives)? The project will employ an interdisciplinary strategy, where descriptions of the actual state and development of the clinical reality of PGT is combined with theoretical analytical perspectives from psychology, caring science and ethics. An important part of the project´s methodology is to use the combined results from all of the studies for designing and trying out new organisational and educational practices regarding PGT and GC, and to evaluate these. The methodological perspectives will be combined in the final analysis, and the last year will be devoted to producing a final analysis which can be used for the construction of practically usable guidelines for ethical and quality assessments in the practical clinical reality of PGT. As far as we know, this research-approach is unique regarding its methodological set-up and combination of competences both nationally and internationally.

Descriptive studies
Study 1: Interview-survey of the actual organisation and ideology of PGT for cancer and Huntington´s disease in Sweden. We expect interesting differences to be found on both these points, both between different centres and between different categories of staff. All staff principally involved at all centres in Sweden involved in PGT is invited (former staff of importance will also be invited) to participate. The population is identified through written and verbal contacts with the centres. The questions asked concern how the practice came about, how it has evolved regarding organisation and involved competence, and on what grounds such actions have been undertaken. Tentative results will be sent to the respondents for comment in order to secure accuracy and avoid misinterpretation. Regarding PGT for cancer, this part of the project has already been initiated with local funding, and is carried out by AB supervised by CM (who will carry out the interviews in Göteborg), and assisted by KM. Besides being of interest as such, the final results will be used as a background for the local studies at the Departments of Clinical Genetics and Oncology in Göteborg described below.
 Studies 2-5: Perception among staff and patients of information-processing, well-being, caretaking, changes of interests and ethical complications in PGT. We expect significant differences regarding these aspects in relation to different categories of people - in particular staff and patients.Methods used will be questionaires (patients) and interviews (staff and selected patients). All involved staff at the two centres will be invited for answering questions of how they perceive of the activity of GC and PGT in different stages, what they see as the point of the practice, how patients seem to be affected in terms of well-being, and how well information is understood and processed by patients. The reported perceptions will be related to differences of sex, age, professional function and degree of foreknowledge regarding genetic matters. All patients in different stages of genetic investigation at the two centres during a period of one year will then be similarily invited to answer similar questions - in particular how well they think they have managed to understand and process given information. Some of these patients will then be selected for invitation to participate in "deeper" interviews in order to strengthen the basis for interpreting the results from the questionaire-study. In order not to direct the thoughts of the respondents too much, the questions will be rather open-ended and general in nature, leaving a rather large room for associations and intiatives of the respondents and (in the case of interviews) follow-up questions. The reported perceptions will be related to if a patient is a relative of another patient, differences of sex, age, cultural/ethnic background, motives for requesting testing, degree of foreknowledge regarding genetic matters, ethical values, psycho-social situation etc. The results of these studies will be used for working out a general picture of how different parties in different stages have perceived (1) the possibility of achieving a clear picture of what goal the patient tries to achieve through the PGT and to what extent the information given to the patient have been relevant in the light of this goal, (2) the ability of the patient to comprehend the given information in a way which may be used by the patient for making rational decisions in light of the goals they are trying to achieve. These studies will be planned jointly by the team and carried out by CM, AB, KM, EF, U H-U (whoever is the least biased for a particular study). This part of the project has already started, through a currently conducted (locally funded) study (including a completed pilot study) of psycho-social needs and perception of given information among all patients who have completed the process of oncogenetic investigation in Göteborg (carried out by EF and KM).
 Study 6: Continuous revision, follow-up and reevaluation of the organisation of PGT. The above mentioned aspects are here related to the possible offering of new tests, changes in caretaking, organisation or the handling of information undertaken on the basis of the results of the above-described studies, as well as ethical aspects. This part of the project will be undertaken jointly by the project team, with the principally involved persons at the respective centres (JW and AB) as primarily responsible.
 Study 7: Educational implementation of the practical knowledge of genetic counselling and the process of professionalisation of genetic counsellors in Sweden and United Kingdom. This part of the project will relate the above-mentioned education for genetic counsellors to the practice of GC examined in the above-mentioned studies, and compare it to a similar  education in Preston, UK. The study will be carried out by KB and U H-U, assisted by CM, through a combination of participatory observation, interviews with students and teachers, and analysis against the background of other parts of the project.
 There is a methodological problem involved in the investigation of the views and perceptions of relatives, since those relatives who can be contacted through the centres already have been informed about the genetic risk and have decided to make contact with health care on the basis of this. In order to achieve a more comprehensive picture of how people view the prospect of being contacted by relatives or health care about discovered genetic risks, we are therefore planning a questionnaire-study aimed at a statistical sample of the Swedish population. The initial planning, collection of data and initial statistical analysis of this part of the project will be undertaken in collaboration with specially recruited expert consultants from SIFO or SCB.
 Collected data will otherwise not primarily be analysed from a statistical point of view (although some rudimentary statistical systematisation will, of course, be needed). The main thrust will be qualitative analyses and interpretations on the basis of conceptual frameworks from bioethics, moral philosophy, caring science and psychology. In particular, we want to assess to what extent various parties describe the goals of the practice of GC and PGT in different ways, what difficulties of achieving these goals they point to, and what can be said from this regarding the resolution of various conflicts of interest in connection to the main questions of the project mentioned above.

Normative studies
The descriptive part of the project will provide a factual basis for the analysis of underlying ethical and evaluative issues arising out of the tension between the traditional medical ethical ideal of merely respecting patient autonomy in the pursuit of promotong health and well-being, and the more ambitious ideal of GC to actively promote  autonomy as well. These issues are theoretical and require systematic analysis of concepts of autonomy, informed consent, well-being and rationality, as well as normative analysis of ethical principles in which these concepts appear. Methodologically, this part of the project will primarily be based on studies of the literature in the field, with the help of argumentative and conceptual analysis. However, the final analyses will also involve the use of data and analyses from the descriptive studies. This endeavour connects the project to lively debated basic issues in the international debate on bioethics, moral philosophy and decision theory, which need to be thoroughly analysed. Our intention is therefore to involve in the project team a research student in practical philosophy (NJ), who will have this part of the project as his main task under the supervision of CM. The work will be focus on two primary questions in relation to the clinical reality of PGT and GC.
 The first of these questions concerns the value of PGT and GC for individual people. To what extent can genetic information benefit an individual in terms of autonomy and well-being and how should conflicts between these values be handled? What is the significance of the medical, psychological and social situation of the person in question, as well as his or her initial understanding of genetic and medical facts? Must the information which may be obtained through a certain test be of a certain quality (precise, corroborated, informative etc.) in order for the test to be of any benefit? Are all aspects of human well-being and autonomy relevant from a medical point of view, or should health care limit itself to meeting only certain kinds of needs? In particular, can the aim of GC to actively promote the personal autonomy of patients give room for traditional requirements on health care not to offer procedures which are bad for people (in terms of health and well-being)?
 The second question is about interpersonal conflicts of interest due to the fact that genetic information always is about several people. How should the well-being, integrity and autonomy of registered patients (i.e., those who have a case record) be seen in relation to the same interests of relatives who have not yet been made aware of the genetic risk? In connection to this general issue, it is of particular interest to conduct a closer analysis of ethical conflicts where one person´s autonomy cannot be fully respected without the restriction of another person´s autonomy. This is highly relevant, for example, in the case where it is clear that a patient is unwilling to inform relatives about a revealed genetic risk, although the patient knows that the relatives would be very interested in this information. In connection to these kinds of cases, we will also investigate what difference it would make to analyse such conflicts from the perspective of social justice and more traditional welfare-based values in medical ethics.
 In order to realise the basic aims of the project, the result of the normative studies will be combined with the results from the descriptive studies in the final analysis. However, the descriptive studies will also be constructed in such a way that they may uncover information relevant for the normative issues. Theories and concepts from ethics and argumentative as well as conceptual analysis will therefore be used in the construction of questions and analytical schemes in the descriptive part of the project.

Research ethical aspects
Contacts with patients may cause anxiety and guilt-feelings and must therefore be handled very carefully. The ongoing study (including a completed small pilot study) of psycho-social needs of former oncogenetic patients indicate that this is possible if the project has access to psychological expertise who can be contacted by the respondents in case of need. The project-team has two members who can assume such a role, one for each of the involved centres. In any case, it is important to minimise the burden which the project may lay on patients. For this reason, the most sensitive contacts will not be taken until we have assessed the data collected from already ongoing or less sensitive studies. We therefore estimate that investigations involving patients undergoing GC will not be undertaken until the third year of the project. In other words, application to and approval of an ethics committee will not be actualised until this specific part of the project is planned in detail. Contacts with health care staff are handled according to the ethical guidelines of the Swedish Council for Research in the Humanities and Social Sciences (i.e., they are viewed as respondents/participants rather than human subjects). No interview- or questionnaire-studies are made without the obtaining of informed consent. All data from these investigations are treated as confidential information and stored in a safe place. All data are anonymised before any publication of results. Should the need to publish quotes (or descriptions which make the identification of individuals possible) from interviews arise, this is not undertaken without the prior explicit informed consent for this specific purpose from the person in question.
 


PUBLICATIONS, PRESENTATIONS AND ACTIVITIES FROM THE PROJECT

Publications and presentations
Activities


To the top         To project leader        To the Dept. of Philosophy        To Dept. of Oncology      To Dept. of Clinical Genetics